Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

24 Jan 26

Updated

26 Jun 26

Views

Not Invested

Shared on 26 Jun 26

Fair value Increased 6.39%

PPGN: Raised Price Views Will Likely Overstate Takeover Hopes

PolyPeptide Group draws takeover buzz after reports that big private equity firms are taking a look, but expectations may be running ahead of what the business can deliver. With analysts nudging their views higher, the key question is how much room is left for upside if growth or execution slips.

2 views

Fair Value vs Share Price

CHF 38.45

vs CHF 49.3528.3% overvalued

19.4%

Revenue growth

11.4%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on PolyPeptide Group

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Reasonable growth potential with adequate balance sheet.

Market capCHF 1.6b

PB5.2x

Estimated Growth14.2%

Dividend Yield0%

Full analysis

CEO & management

Juan Gonzalez

CEO

3.7yrs

CEO Tenure

Operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally.